The Opportunity: DPR CEO Jing DiPiero learned that a new cancer drug, developed by Blaze Bioscience, is undergoing FDA approval in the U.S. Jing met with the CEO to discuss the opportunity to broaden the positive impact and potential revenue of the company’s drug in China by applying for China FDA approval as well. Jing … Read moreIndustries
“We are excited about expanding into China and look forward to working with Jing and DPR.”
- Heather Franklin, President and CEO, Blaze Bioscience